Clinical Symptoms of Mitral Valve Prolapse Are Related to Hypomagnesemia and Attenuated by Magnesium Supplementation


      Mitral valve prolapse syndrome (MVP) is a frequent disorder characterized by a number of complaints which lessen the quality of life. The pathogenesis of MVP symptoms has not been fully elucidated. Hyperadrenergic activity and magnesium deficiency have been suggested. This study was designed to verify the concept that heavily symptomatic MVP is accompanied by hypomagnesemia and to elucidate whether magnesium supplementation alleviates the symptoms and influences adrenergic activity. We assessed serum magnesium in 141 subjects with heavily symptomatic primary MVP and in 40 healthy controls. Decreased serum magnesium was found in 60% of patients and in 5% of controls (p <0.0001). Patients with low serum magnesium were subjected to magnesium or placebo supplementation in a double-blind, crossover fashion. Typical symptoms of MVP (n = 13), intensity of anxiety, and daily excretion of catecholamines were determined. After 5 weeks, the mean number of symptoms per patient decreased from 10.4 ± 2.1 to 5.6 ± 2.5 (p <0.0001), and a significant reduction in weakness, chest pain, dyspnea, palpitations, and anxiety was observed. Increased noradrenaline excretion before and after magnesium was seen in 63% and 17% of patients, respectively (p <0.01). Mean daily excretion of noradrenaline and adrenaline was significantly diminished after magnesium. It is concluded that many patients with heavily symptomatic MVP have low serum magnesium, and supplementation of this ion leads to improvement in most symptoms along with a decrease in catecholamine excretion.
      This study reveals a high incidence (60%) of hypomagnesemia in 141 patients with symptomatic mitral valve prolapse. After controlled oral magnesium supplementation for 5 weeks in 70 patients, most symptoms were significantly alleviated along with diminution of catecholamine excretion.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Dürlach J
        • Dürlach V
        Idiopathic mitral valve prolapse and magnesium. State of the art.
        Mag Bull. 1986; 8: 156-169
        • Dürlach J
        • Lutfalla G
        • Poenaru S
        • Reba A
        • Henrotte JG
        • Fabiani F
        • de Vernejoul F
        Latent tetany and mitral valve prolapse due to chronic primary magnesium deficit.
        in: Halpern MJ Dürlach J Magnesium Deficiency. First European Congress on Magnesium, Lisbon 1983. Karger, Basel1985: 102-112
        • Galland LD
        • Baker SM
        • McLellan RK
        Magnesium deficiency in the pathogenesis of mitral valve prolapse.
        Magnesium. 1986; 5: 165-174
        • Simoes-Fernandes J
        • Pereira T
        • Carvalho J
        • Fransca A
        • Andrade R
        • Noqueira-Pereira J
        • Rodrigues JC
        • Laires MJ
        • Halpern MJ
        Therapeutic effects of a magnesium salt in patients suffering from mitral valve prolapse and latent tetany.
        Magnesium. 1985; 4: 283-290
        • Kłoś J
        • Lichodziejewska B
        • Budaj A
        • Grudzka K
        The results of treatment of magnesium-calcium metabolic disorders in mitral valve prolapse syndrome (in Polish).
        Pol Tyg Lek. 1988; 43: 1330-1333
        • Boudoulas H
        • Kolibash AJ
        • Baker P
        • King BD
        • Wooley CF
        Mitral valve prolapse and the mitral valve prolapse syndrome: a diagnostic classification and pathogenesis of symptoms.
        Am Heart J. 1989; 118: 796-818
        • Boudoulas H
        • Reynolds JC
        • Mazzaferri E
        • Wooley CF
        Metabolic studies in mitral valve prolapse syndrome. A neuroendocrine-cardiovascular process.
        Circulation. 1980; 61: 1200-1205
        • Pasternac A
        • Tubau JF
        • Puddu PE
        • Krol RB
        • de Champlain J
        Increased plasma catecholamine levels in patients with symptomatic mitral valve prolapse.
        Am J Med. 1982; 73: 783-789
        • Levine RA
        • Triulzi MO
        • Harrigan P
        • Weyman AE
        The relationship of mitral annular shape to the diagnosis of mitral valve prolapse.
        Circulation. 1987; 75: 756-767
        • Jeresaty RM
        Mitral valve prolapse. An update.
        JAMA. 1985; 254: 793-795
        • Spielberger CD
        Preliminary Test Manual for the State-Trait Anxiety Inventory.
        Consulting Psychologists, Palo Alto, CA1973
        • von Studnitz W
        Fluorometrische Bestimmung von Adrenalin und Noradrenalin in Urin.
        in: Breuer H Hamel D Krüskemper HL Methoden der Hormonbestimmung. Georg Thieme Verlag, Stuttgart1975: 150-154
        • Boos N
        • Paschen K
        • Strobel B
        Vergleich zwischen Xylidylblau—Methode und AAS.
        Mag Bull. 1985; 7: 163-169
        • Classen HG
        • Achilles W
        • Bachem MG
        • Conradt A
        • Fehlinger R
        • Gossmann HH
        • Günther T
        • Münzenberg KJ
        • Paschen K
        • Schreiber G
        • Schroll A
        • Spätling L
        • Wischnik A
        • Zümkley H
        Magnesium: indications concerning diagnosis and treatment in man. Reccommendations of a Commission of Experts of the Geselschaft für Magnesiumforschung e.V. Symposium held in Münich on 29–30 November 1985.
        Mag Bull. 1986; 8: 117-135
        • Reinhart RA
        Magnesium metabolism. A review with special reference to the relationship between intracellular content and serum levels.
        Arch Intern Med. 1988; 148: 2415-2420
        • Whang R
        Routine serum magnesium determination—a continuing unrecognized need.
        Magnesium. 1987; 6: 1-4
        • Elin RJ
        Overview of problems in assessment of magnesium salts.
        in: Altura BM Dürlach J Seelig MS Magnesium in Cellular Processes and Medicine. Karger, Basel1987: 67-76
        • Cohen L
        • Bitterman H
        • Grenadier E
        • Laor A
        • Lahat N
        • Palant A
        Idiopathic magnesium deficiency in mitral valve prolapse.
        Am J Cardiol. 1986; 57: 486-487
        • Frances Y
        • Collet F
        • Luccioni R
        Long term follow up of mitral valve prolapse and latent tetany. Preliminary data.
        Magnesium. 1986; 5: 175-181
        • Gerard R
        • Luccioni J
        • Gatau-Pelanchon G
        • Duport G
        • Julien G
        • Bouteau JM
        • Chabrillat Y
        • Duport MY
        Prolapsus valvulaire mitral et spasmophilia chez l'adulte.
        Arch Mal Coeur. 1979; 72: 715-720
        • Kłoś J
        • Lichodziejewska B
        • Grudzka K
        • Budaj A
        • Śliwińska J
        • Ceremużyński L
        Magnesium-calcium metabolic disorders in the mitral valve prolapse syndrome (in Polish).
        Pol Tyg Lek. 1988; 43: 1326-1329
        • Coghlan HC
        • Natello G
        Erythrocyte magnesium in symptomatic patients with primary mitral valve prolapse: relationship to symptoms, mitral leaflet thickness, joint hypermobility and autonomic regulation.
        Magnesium Trace Elem. 1992; 10: 205-214
        • Vormann J
        • Forster R
        • Günther T
        • Ebel H
        Lipolysis-induced magnesium uptake into fat cells.
        Mag Bull. 1983; 5: 39-41
        • Seelig MS
        Magnesium Deficiency in the Pathogenesis of Disease.
        Plenum Press, New York1980
        • Carney RM
        • Freedland KE
        • Ludbrook PA
        • Saunders RD
        • Jaffe AS
        Major depression, panic disorder and mitral valve prolapse in patients, who complaints of chest pain.
        Am J Med. 1990; 89: 757-760
        • Herbaczynska-Cedro K
        • Gajkowska B
        Effect of magnesium on myocardial damage induced by epinephrine. Ultrastructural and cytochemical study.
        Cardiosci. 1992; 3: 197-203
        • Zdanowicz MM
        • Barletta MA
        Protective role of magnesium in catecholamine-induced arrhythmia and toxicity in vitro.
        Mag Res. 1991; 4: 153-162
        • Caspi J
        • Coles JG
        • Benson LN
        • Herman SL
        • Diaz RJ
        • Augustine J
        • Brezina A
        • Kolin A
        • Wilson GJ
        The protective effect of magnesium on acute catecholamine cardiotoxicity in the neonate.
        J Thorac Cardiovasc Surg. 1993; 105: 525-531